SSYN.F Stock Overview
Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sensyne Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.002 |
| 52 Week High | UK£1.55 |
| 52 Week Low | UK£0.002 |
| Beta | 1.2 |
| 1 Month Change | -90.34% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| SSYN.F | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -83.5% | -7.3% | -3.5% |
| 1Y | n/a | -11.1% | 20.2% |
Return vs Industry: Insufficient data to determine how SSYN.F performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how SSYN.F performed against the US Market.
Price Volatility
| SSYN.F volatility | |
|---|---|
| SSYN.F Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 10.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SSYN.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SSYN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 158 | Alex Snow | www.sensynehealth.com |
Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for Covid-19 self-monitoring; DBm-Health, a patient to clinician system that allows health care professionals manage patients with diabetes; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company’s products also include MagnifEye that allows reading and analysis of diagnostic tests; SEND, an evidence-based digital charting system for vital-signs observations; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; Support-HF, a prescribed digital therapeutic for monitoring heart failure at home; Sense, a clinical AI algorithm engine; SYNE-COV, a COVID-19 patient outcome algorithm; and SYNE-OPS, a real-time operational patient management algorithm.
Sensyne Health plc Fundamentals Summary
| SSYN.F fundamental statistics | |
|---|---|
| Market cap | US$713.42k |
| Earnings (TTM) | -US$42.65m |
| Revenue (TTM) | US$9.56m |
0.1x
P/S Ratio0.0x
P/E RatioIs SSYN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SSYN.F income statement (TTM) | |
|---|---|
| Revenue | UK£7.81m |
| Cost of Revenue | UK£2.78m |
| Gross Profit | UK£5.03m |
| Other Expenses | UK£39.86m |
| Earnings | -UK£34.83m |
Last Reported Earnings
Oct 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 64.37% |
| Net Profit Margin | -446.13% |
| Debt/Equity Ratio | 0% |
How did SSYN.F perform over the long term?
See historical performance and comparison